Plasmodium vivax malaria

Summary

Plasmodium vivax malaria (MONDO:0005921) is a disease and 46 clinical trials. Top therapeutic interventions include primaquine, chloroquine, and artesunate. A subtype of malaria — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 46

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	Plasmodium vivax malaria
Mondo ID	MONDO:0005921
EFO	EFO:0007445
MeSH	D016780
DOID	DOID:12978
ICD-10-CM	B51
NCIT	C34800
SNOMED CT	27052006
UMLS	C0024537
MedGen	6186
GARD	0024255
Is cancer (heuristic)	no

Also known as: vivax malaria

Disease family

This is a subtype of malaria. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › disease of primarily extrinsic mechanism › infectious disease › parasitic infectious disease › protozoa infectious disease › malaria › Plasmodium vivax malaria

Related subtypes (6): Plasmodium ovale malaria, Plasmodium malariae malaria, mixed malaria, cerebral malaria, blackwater fever, Plasmodium falciparum malaria

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

Drugs indicated for this disease

0 approved, 13 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.

Drug	Development status
Amodiaquine	Phase 3 (in late-stage trials)
Artemether	Phase 3 (in late-stage trials)
Artenimol	Phase 3 (in late-stage trials)
Artesunate	Phase 3 (in late-stage trials)
Chloroquine	Phase 3 (in late-stage trials)
Chlorproguanil	Phase 3 (in late-stage trials)
Dapsone	Phase 3 (in late-stage trials)
Lumefantrine	Phase 3 (in late-stage trials)
Piperaquine	Phase 3 (in late-stage trials)
Primaquine	Phase 3 (in late-stage trials)
Pyrimethamine	Phase 3 (in late-stage trials)
Sulfadoxine	Phase 3 (in late-stage trials)
Tafenoquine	Phase 3 (in late-stage trials)

Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Tinidazole.

Clinical trials & evidence

Clinical trials

Clinical trials: 46.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	14
PHASE4	13
PHASE3	11
PHASE2	4
PHASE1	4

Top trials by phase / activity

NCT	Phase	Status	Title
NCT04704999	PHASE4	RECRUITING	Southeast Asia Dose Optimization of Tafenoquine
NCT05788094	PHASE4	RECRUITING	ACT vs CQ With Tafenoquine for P. Vivax Mono-infection
NCT07060794	PHASE4	NOT_YET_RECRUITING	Tafenoquine and ACTs (TADORE- Plus)
NCT07468513	PHASE4	RECRUITING	Primaquine for Vivax Malaria in G6PD Intermediate and Deficient Cases.
NCT01107145	PHASE4	TERMINATED	Efficacy of Artemisinin Combination Therapies for the Treatment of Uncomplicated P. Vivax in Pregnancy in Brazil (PAACT-PV)
NCT01178021	PHASE4	COMPLETED	Estimating the Risk of Plasmodium Vivax Relapses in Afghanistan
NCT01887821	PHASE4	COMPLETED	Antimalarial Drug Susceptibility and Molecular Characterization of Plasmodium Vivax Isolates in Vietnam
NCT02118090	PHASE4	COMPLETED	Assessment of Plasmodium Vivax Chloroquine Resistance in Cambodia:
NCT02876549	PHASE4	COMPLETED	G6PD Assessment Before Primaquine for Radical Treatment of Vivax Malaria
NCT03916003	PHASE4	COMPLETED	Reducing the Risk of P. Vivax After Falciparum Infections in Co-endemic Areas
NCT04706130	PHASE4	COMPLETED	Rigorous Assessment of P. Vivax Relapses and Primaquine Efficacy for Radical Cure
NCT06044805	PHASE4	COMPLETED	Therapeutic Efficacy of Chloroquine Plus Primaquine in the Treatment of Uncomplicated Plasmodium Vivax
NCT06575647	PHASE4	COMPLETED	Vivax Elimination With Tafenoquine (VET) Study
NCT05690841	PHASE3	RECRUITING	FocaL Mass Drug Administration for Vivax Malaria Elimination
NCT06148792	PHASE3	RECRUITING	A Revised Tafenoquine Dose to Improve Radical Cure for Vivax Malaria
NCT00158548	PHASE3	COMPLETED	ACT With Chloroquine, Amodiaquine & Sulphadoxine-pyrimethamine in Pakistan
NCT00158561	PHASE3	COMPLETED	Chlorproguanil/Dapsone Compared With Chloroquine and SP for Vivax Malaria
NCT00158587	PHASE3	COMPLETED	Eight Week Primaquine Regimen for the Treatment of Vivax Malaria
NCT00682578	PHASE3	COMPLETED	A Comparative Study of Artekin With Standard Malarial Treatment Regimes in Afghanistan
NCT01074905	PHASE3	COMPLETED	Study on the Treatment of Vivax Malaria
NCT01288820	PHASE3	COMPLETED	Study of ACTs Plus Primaquine for Uncomplicated Plasmodium Vivax Malaria
NCT01625871	PHASE3	COMPLETED	Artemether/Lumefantrine and Vivax Malaria
NCT01640574	PHASE3	COMPLETED	Comparison Between 7 and 14 Day Primaquine Combined With Dihydroartemisinin-piperaquine or 3 Day Chloroquine Radical Cure of P. Vivax (BPD)
NCT04411836	PHASE3	COMPLETED	Effectiveness of Novel Approaches to Radical Cure With Tafenoquine and Primaquine
NCT07373301	PHASE2	NOT_YET_RECRUITING	Phase IIa/b Trial of PvCS/Montanide ISA-51 Malaria Vaccine in Adults in Chocó, Colombia
NCT02123290	PHASE2	COMPLETED	DSM265 Phase IIa Investigation Treating Plasmodium Falciparum or Vivax
NCT02696928	PHASE2	WITHDRAWN	Methylene Blue Against Vivax Malaria in Ethiopia
NCT03529396	PHASE2	COMPLETED	Safety and Efficacy of Different Regimens of Primaquine on Vivax Malaria Treatment in G6PD Deficient Patients
NCT00295581	PHASE1	COMPLETED	PpPfs25/ISA51 and ScPvs25/ISA51 Vaccines for Malaria
NCT00935623	PHASE1	COMPLETED	Clinical Trial for the Development of a Safe Malaria Challenge Model That Can be Reproduced in Humans
NCT01218932	PHASE1	COMPLETED	Pharmacokinetic Study of Primaquine and Chloroquine in Healthy Subjects
NCT01780753	PHASE1	COMPLETED	Primaquine Pharmacokinetics in Lactating Women and Their Infants
NCT00138489	Not specified	TERMINATED	Papua New Guinean Duffy Negativity And Vivax Malar
NCT00157833	Not specified	COMPLETED	A Randomized Trial of Coartemether and Artekin for the Treatment of Uncomplicated Malaria in Papua, Indonesia.
NCT00157859	Not specified	COMPLETED	To Evaluate Current Efficacy of Antimalarials Used in Timika, Papua, Indonesia
NCT01076868	Not specified	COMPLETED	Incidence of Vivax Along the Thai Burma Border
NCT01546961	Not specified	COMPLETED	Chloroquine Population Pharmacokinetics in Pre and Post-partum Women
NCT01716260	Not specified	COMPLETED	Safety and Efficacy of Chloroquine and Primaquine for Vivax Malaria in Bhutan
NCT02001428	Not specified	COMPLETED	Malaria in Early Life Study
NCT04222088	Not specified	COMPLETED	TES of Artemether-lumefantrine for Pf and Chloroquine for Pv in the Philippines From 2013-2014

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
PRIMAQUINE	4	54
CHLOROQUINE	4	12
ARTESUNATE	4	4
TAFENOQUINE	4	4
AMODIAQUINE	4	3
ARTENIMOL	4	3
ARTEMETHER	4	2
LUMEFANTRINE	4	1
ARTEMISININ	3	3
PIPERAQUINE	3	1
DSM-265	2	1
CHEMBL3932056	0	3
CHEMBL470034	0	3
CHEMBL511326	0	3
CHEMBL5178921	0	3
CHEMBL5206150	0	3
CHEMBL5284664	0	3
CHEMBL5288857	0	3
CHEMBL4740236	0	2
CHEMBL5207162	0	1